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A s one of the screening tests routinely performed prior to birth,  non-invasive prenatal genetic test-
ing (NIPT) measures cell-free DNA in maternal blood 
in order to estimate the possibility that the fetus may be 
predominantly affected by trisomy 21,  trisomy 18,  or 
trisomy 13 [1 , 2].  As a screening test,  it has clear 
advantages over amniocentesis,  since it can be per-
formed safely at an earlier stage from a simple blood 
draw.  However,  it is not generally known that rare 
chromosomal disorders,  such as fetal microdeletion / 
duplication syndrome or trisomy mosaicism,  may be 
found in NIPT-positive and -indeterminate cases.  We 
herein report on 2 cases in which trisomy 21 mosaicism 
and 18q deletion syndrome were definitively diagnosed 
by the amniotic fluid chromosome test performed sub-
sequent to obtaining abnormal NIPT results.
Case 1
The mother was a 36-year-old woman,  with 2 preg-
nancies and 0 births.  The prior year,  she had suffered 
spontaneous miscarriage at 10 weeks’ pregnancy due to 
fetal trisomy 9.  In vitro fertilization was performed this 
time and her pregnancy progressed without incident.  
No obvious fetal abnormalities were found on early 
pregnancy ultrasonography at 11 weeks and 2 days of 
pregnancy.  She requested for NIPT after precise genetic 
counseling,  and NIPT was performed at 11 weeks and 
4 days of gestation.  Consequently,  her blood screened 
“positive” for trisomy 21.  The concentration of chro-
mosome 21 was 17.29% for the fraction of fetal cell-free 
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DNA and 15.86% based on the Z-Score; this is half the 
concentration estimated from the fetal genome rate for 
the standard trisomy type (Fig. 1).  An amniotic fluid 
chromosome test was performed at 17 weeks and 2 days 
of pregnancy and yielded a karyotype analysis of 47,  
XY,  + 21 [4] / 46,  XY,  [12] (Fig. 2).  Of the 16 cells,  
4 cells had trisomy 21,  while 12 cells had normal chro-
mosome counts,  and trisomy 21 mosaicism was diag-
nosed.  In mosaic trisomy it is believed that the pheno-
type is affected when the proportion of abnormal cells 
exceeds 20%; in the present case,  over 20% cells sam-
pled showed trisomy 21.  Fetal ultrasonography at 
20 weeks of pregnancy indicated no obvious abnormal 
findings.  She was provided genetic counseling concern-
ing the facts that it could not be said with certainty that 
the disease was mild,  that no morphological abnormal-
ities were observed by ultrasound and that the mosaic 
ratio in amniotic fluid cells was not always the same in 
the fetus,  making it difficult to predict the severity of 
the phenotype.  After much agonizing,  a 400-g male 
fetus was selectively aborted at 21 weeks of pregnancy.  
A total of 5 genetic counseling sessions were performed.  
Case 2
The mother was 28 years old,  with 1 pregnancy and 
0 births.  The pregnancy was natural.  A nuchal translu-
cency thickness of 5 mm was noted at 11 weeks of 
pregnancy and NIPT was performed at 13 weeks and 
6 days of pregnancy,  with the detection of early preg-
nancy ultrasound abnormalities as an indication.  The 
result was indeterminate due to the deletion of the 
18q22.1-q22.3 region (Fig. 3).  Amniotic fluid chromo-
some testing was performed at 16 weeks and 0 days of 
pregnancy and yielded the karyotype 46,  XY,  r (18) 
(p11.2q21.3) (Fig. 4),  i.e.  a chromosome 18 ring.  The 
SNP microarray analysis was arr 18p11.32p11.31 × 1 
and 18q21.33q23 × 1 (Fig. 5).  Partial deletions from the 
end of the short arm to 11.2 as well as from the end of 
the long arm 21.3 to the end were found on the chro-






















Fig. 1　 Z-Score for chromosome 21: Although the Z-Score is 
clearly higher than the cutoff value,  it does not reach the population 
average considered to be positive by the standard trisomy type,  
suggesting a fetal DNA concentration of ambiguous significance.
Fig. 2　 Conventional karyotype analysis of cultured amniocytes shows the fetal karyotype as 47,  XY,  +21 [4] / 46,  XY [12].
mosome.  Because the MBP gene was present at the 
18q22.3 site,  this case was diagnosed as 18q deletion 
syndrome.  Genetic counseling was provided to the 
couple,  concerning the fact that the symptoms of 18q 
deletion syndrome would include growth failure,  cra-
niofacial malformation,  urogenital abnormalities,  limb 
abnormalities,  neurological abnormalities,  and cardiac 
construction abnormalities.  After much agonizing,  a 
320-g male fetus was selectively aborted at 19 weeks 
and 6 days of gestation.  A total of 4 genetic counseling 
sessions were performed.
In both cases,  the subjects became pregnant again 
one year later and underwent NIPT.  The results were 
negative and they continued their pregnancies unevent-
fully.
Human rights statements and informed consent.
All procedures followed were accordance with the ethi-
cal standards of the responsible committee on human 
experimentation (institutional and national) and with 
the Helsinki Declaration of 1975,  as revised in 2008 (5).  
Informed consent was obtained from both patients 
included in this report.
Discussion
We experienced 2 cases with definitive diagnoses of 
trisomy 21 mosaicism and 18q deletion syndrome trig-
gered by NIPT.  Each case had 2 clinical implications.  
First,  at the NIPT stage,  it was revealed that trisomy 
mosaicism might be found in NIPT-positive cases that 
have lower Z-Scores than those inferred from the frac-
tion of fetal cell-free DNA in the case of standard tri-
somy.  Second,  it is possible that microdeletion syn-
drome could be the reason for an indeterminate NIPT 
result.
Chromosome mosaicism is a state in which a cell 
population having a normal karyotype and a cell popu-
lation having an abnormal (e.g.,  trisomy) karyotype 
coexist in one individual.  While mosaic chromosomal 
abnormalities are generally detected by G banding,  they 
may also be detected by interphase nucleus FISH or 
array CGH testing.  Compared to standard trisomy-type 
infants,  the phenotype of mosaic-type infants is milder 
and the severity thereof is said to change depending on 
the prevalence of cells with chromosomal abnormalities 
[3].  Although it is said that the phenotype is affected 
when the proportion of abnormal cells exceeds 20%,  
the amniotic fluid cells analyzed by tests performed to 
diagnose mosaicism may grossly over- or underestimate 
this proportion depending on the tissues where the 
abnormality is prominent in the particular individual.  
Even if mosaicism is found in amniotic fluid cells,  there 
is believed to be a 50% chance that the fetus will have a 
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Fig. 3　 The MPS method result shows the deletion of the 18q22.1-q22.3 region.
Fig. 4　 Conventional karyotype analysis of cultured amniocytes 
shows the fetal karyotype as 46,  XY,  r (18) (p11.2q21.3).
similar mosaic in the chromosome mosaicism,  making 
it difficult to practically predict the severity of the phe-
notype [4 , 5].  Precise fetal ultrasonography is signifi-
cantly unlikely to extract morphological abnormalities,  
as seen in the standard trisomy type; in fact,  Trisomy 
21 fetuses are said to exhibit findings comparable to 
those of a normal fetus [6].  Therefore,  when chromo-
some mosaicism is found on amniocentesis,  it is 
important to confirm the presence or absence of mor-
phological abnormalities by precise fetal ultrasonogra-
phy,  estimate the phenotype including the result,  and 
provide this information.  Furthermore,  it is difficult to 
investigate the karyotype of cells throughout the body,  
even when examined in detail after birth,  as far as the 
phenotype and appearance of the baby can be under-
stood.  Although a detailed fetal ultrasonography was 
performed twice in our case,  no morphological abnor-
malities were found,  confirming that ultrasonography 
is of limited use in the diagnosis of trisomy mosaicism.  
On the other hand,  18q deletion syndrome is a rare 
chromosomal aberration syndrome,  with a frequency 
of 1/40,000 and a very diverse phenotype.  Many cases 
are associated with growth failure,  characteristic facial 
features,  limb abnormalities,  genitourinary malforma-
tions,  and neurological abnormalities.  Mental retarda-
tion has been observed as a neurological abnormality in 
almost all cases,  with developmental delays accompa-
nied by hypotonia,  hearing loss,  convulsions,  and 
nystagmus also having been reported [7 , 8].  While it is 
reported that the degree of developmental delay varies 
(IQ 40-85) with the possibility of only mild develop-
mental delays and learning disabilities,  some reports 
indicate that more than half have IQs of 30-50 [9 , 10].  
Although most of the chromosome deletion sites are at 
the ends of 18q21.2→qter,  these clinical findings are 
associated with myelination failure in cerebral white 
matter,  due to a defect in the myelin basic protein 
(MBP) gene present in 18q22.3 and cerebral atrophy 
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Fig. 5　 SNP microarray result showing the presence of the 18q deletion syndrome.  A,  A full view of chromosome 18; B,  Detailed 
results of SNP microarray analysis,  showing (from top to bottom) smooth signal,  log2 ratio,  and copy number state, identifying the deletion 
of the 18p11.32p11.31 and 18q21.33q23 regions.
associated with white mass loss [11].  Despite these var-
ious abnormalities,  the prognosis for life is relatively 
good.  The phenotype of 18q deletion syndrome is 
diverse and follows the basic rule of “the larger the dele-
tion region,  the more severe the symptoms”; more 
precise relationships between phenotype and deletion 
site genes are still being clarified [12 , 13].
When NIPT is performed for the purpose of detect-
ing numerical abnormalities on chromosomes 13,  18 
and 21,  the Massively Parallel Sequencing (MPS) 
method determines the number of DNA fragments 
derived from each chromosome,  obtains the number of 
DNA fragments derived from each chromosome,  and 
calculates the ratio of the number of DNA fragments of 
the target chromosome to the total amount of fragments 
detected.  In order to ensure measurement accuracy,  a 
cutoff value using the Z-Score is set as an index,  by cal-
culating the difference from the average of multiple 
normal karyotype samples,  measured at the same time,  
to see how many fold off the values of the sample to be 
measured are from the standard deviation.  Normally,  
trisomy 21 uses a Z-Score of 3 as the cutoff value,  with 
those above this value considered trisomy 21 positive 
[14].  Although the relationship between the fetal DNA 
concentration and Z-Score resulting from the MPS 
analysis was clearly higher than the cutoff value in Case 
1,  as illustrated in Fig. 2,  it did not reach the population 
average of standard trisomy fetuses,  suggesting that our 
case was not a normal positive case.  It is said in Japan 
that indeterminate results occur in 0.23% [15],  with 
“vanishing twin” death in the early stages of pregnancy,  
fetal or maternal somatic cell mosaicism,  placental 
mosaicism,  maternal tumors,  maternal autoimmune 
diseases,  etc.  having been reported as factors of inde-
terminate results,  if the cell-free DNA concentration 
from the fetus in the maternal blood is less than 4% 
[16-19].  In Case 2,  as illustrated in Fig. 3,  the fragment 
amount of the entire chromosome 18 was abnormally 
low and it was already known via NIPT that it was not a 
normal case.  Unfortunately,  there is no specific crite-
rion to determine whether a non-trisomy case is nega-
tive or indeterminate.  This case was reported as inde-
terminate due to the partial deletion of chromosome 18,  
which has a different meaning from indeterminate sta-
tus because of low fetal DNA blood concentration of a 
normal fetus.  As far as we know,  only one other case of 
18p deletion syndrome [20] has been diagnosed with 
NIPT,  namely the first report of 18q deletion syndrome.  
The present study is the first report on trisomy mosa-
icism detected by NIPT.  It is difficult to describe to 
pregnant patients the possibility of facing such results 
before they undergo the NIPT test.  Certainly,  more 
consideration needs to be made as to how genetic coun-
selors should deal with positive and indeterminate 
results.
When NIPT was first launched in the United States 
in 2011,  it was a non-deterministic test that estimated 
the likelihood of having trisomy 21,  trisomy 18,  and 
trisomy 13.  However,  it is currently possible to test for 
the presence or absence of fetal single-gene disease by 
examining multiple genes in fetal cell-free DNA,  con-
tained in maternal blood,  in addition to sex chromo-
some testing,  chromosomal microdeletion,  and dupli-
cation syndrome.  Mutations in 25 genes that cause fetal 
bone system diseases,  neuromuscular diseases,  malfor-
mative syndrome,  etc.  have been confirmed from pre-
natal maternal blood samples,  with 44 genetic diseases 
currently being tested [21].  This suggests that genetic 
testing,  which was traditionally premised on postnatal 
testing,  is now possible with prenatal testing using 
NIPT.  With advances in prenatal diagnosis technology,  
genetic counseling is becoming more complex,  both in 
terms of science and ethics,  resulting in concerns as to 
whether the current system of genetic counseling is ade-
quate.
Conclusion
With NIPT,  the Z-score is elevated to twice the frac-
tion of fetal cell-free DNA,  if the fetus is of the standard 
trisomy type,  whereas the Z-Score is approximately half 
that of the standard trisomy type if it is a mosaic type,  
and significantly lower than the cutoff value if it is 
monosomy.  Today’s genetic counseling requires more 
expertise in communication and ethics as well as genet-
ics because NIPT is not just a simple “yes-no” test; it 
can also present totally unexpected results.  It is essen-
tial to ensure a high-quality genetic counseling system 
that enables a couple to be in an acceptable psychologi-
cal state and to make autonomous decisions within a 
limited time,  even if a rare chromosomal disease is 
found.
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